Use of Tenofovir Alafenamide/Emtricitabine/Elvitegravir-Cobicistat in HIV-Naive Patients with Advanced Disease: GENIS Study
Authors:
- Javier Perez StachowskiJSJavier Perez Stachowski
- David Rial CresteloDCDavid Rial Crestelo
- Ana Moreno ZamoraAZAna Moreno Zamora
- Noemi CabelloNCNoemi Cabello
- Pablo RyanPRPablo Ryan
- Nuria Espinosa AguileraNANuria Espinosa Aguilera
- Otilia BisbalOBOtilia Bisbal
- Maria Jesus Vivancos GallegoMGMaria Jesus Vivancos Gallego
- Maria Jose NuñezMNMaria Jose Nuñez
- Jesus TroyaJTJesus Troya
- Montserrat DominguezMDMontserrat Dominguez
- Julian Olalla SierraJSJulian Olalla Sierra
Open Access
- 25 August 2022
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (17) , 4994
Abstract
Objective: The primary endpoint of the study was to determine the proportion of patients with HIV RNA < 50 copies/mL at 48 weeks. Design: Phase IV, multicentric, open-label, single-arm clinical trial of participants recruited in 2018–2019 to evaluate the efficacy and safety of tenofovir alafenamide/emtricitabine/elvitegravir-cobicistat (TAF/FTC/EVG-c) as first-line treatment in HIV-1 infected naïve participants with advanced disease. Methods: Adverse events were graded according to the Division of AIDS scale version 2.0. Quantitative variables were recorded as median and interquartile range, and qualitative variables as absolute number and percentage. T-Student or Wilcoxon tests were used to analyze intragroup differences of the continuous variables. Results: Fifty participants were recruited with a baseline median CD4 lymphocyte count of 116 cells/µL and a viral load of 218,938 copies/mL. The proportion of patients with viral load <50 copies/mL at week 48 was 94% in the per-protocol analysis, with a median time of 1.9 months to achieve it. Three adverse events attributed to the study drug caused trial discontinuation. Conclusions: the use of TAF/FTC/EVG-c in patients with advanced HIV disease in our study demonstrated efficacy comparable to data from pivotal clinical trials with a good safety profile.Keywords
Funding Information
- Gilead Sciences (GESIDA 9216)
This publication has 15 references indexed in Scilit:
- Mortality and causes of death in people diagnosed with HIV in the era of highly active antiretroviral therapy compared with the general population: an analysis of a national observational cohortThe Lancet Public Health, 2017
- Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trialsThe Lancet, 2015
- Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1–Infected Patients Starting Efavirenz, Lopinavir–Ritonavir, or Atazanavir–Ritonavir Plus Tenofovir/EmtricitabineJAIDS Journal of Acquired Immune Deficiency Syndromes, 2015
- Prevention of HIV-1 Infection with Early Antiretroviral TherapyNew England Journal of Medicine, 2011
- Late presentation of HIV infection: a consensus definitionHIV Medicine, 2010
- The Economic Burden of Late Entry Into Medical Care for Patients With HIV InfectionMedical Care, 2010
- Prospective, Randomized, Open Label Trial of Efavirenz vs Lopinavir/Ritonavir in HIV+ Treatment-Naive Subjects With CD4+<200 cell/mm3 in MexicoJAIDS Journal of Acquired Immune Deficiency Syndromes, 2010
- Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trialThe Lancet, 2009
- Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studiesThe Lancet, 2003
- Survival Benefit of Initiating Antiretroviral Therapy in HIV-Infected Persons in Different CD4+ Cell StrataAnnals of Internal Medicine, 2003